Menu

NIH Turned Down Investigators Who Provoked Ire From Alcohol Industry

An email exchange and an unusual meeting suggest a connection between an institute’s pursuit of industry support and the rejection of a grant application.

Apr 3, 2018
Shawna Williams

ISTOCK, KATARZYNABIALASIEWICZA research funding request to the National Institutes of Health (NIH) may have been quashed as part of an effort to woo industry sponsors of another large study, reports STAT News. The evidence includes an email exchange between the director of the National Institute of Alcohol Abuse and Alcoholism (NIAAA) and an alcohol company executive pledging not to fund the type of study that linked alcohol advertising to teen drinking.

The news report builds on earlier revelations by Wired and The New York Times that NIAAA scientists courted industry funders of a study on the health effects of moderate alcohol consumption by emphasizing the probability that the results would favor such consumption. STAT adds fresh evidence that conflicts of interest may have influenced decisions at the National Institutes of Health (NIH), the largest federal funder of biomedical research.

In the article published by STAT yesterday (April 2), Michael Siegel, a community health researcher at Boston University School of Public Health, gives an account of a 2015 meeting in which he and a coinvestigator on an NIAAA-funded study were summoned to the institute to discuss the work. In the meeting, George Koob, the NIAAA Director, “kept trying to downplay the importance of this research, insisting it was not advertising that made teenagers drink but peer pressure and parents. He was giving us the industry line,” Siegel tells STAT. A new proposal by the coinvestigator to study social media activity by alcohol companies was rejected soon afterward, despite receiving high marks from reviewers.

As it turned out, months after assuming the NIAAA directorship in 2014, Koob had written an email to Samir Zakhari of the Distilled Spirits Council, STAT found, promising that research like Siegel’s advertising project would not be funded again. Zakhari thanked Koob, responding in part, “This kind of research not only wastes precious research dollars but also damages NIAAA’s stature within the NIH community.” In an email to STAT, Koob stated his exchange with Zakhari “was to convey that I had no intention of supporting research that was not of the highest scientific quality.”

In October 2017, Wired reported that for the first time, the alcohol industry was expected to partially sponsor an NIH study, in which thousands of participants would be randomly assigned to either have an alcoholic drink of their choice each day for six years (its cost reimbursed by the investigators), or to abstain. Their health outcomes and mortality rates would be tracked. At the time, five alcohol corporations had pitched in a total of $67 million for the project. Koob and Peggy Murray, who directs the institute’s Global Alcohol Research Program, had both appeared in an Anheuser-Busch InBev video promoting the company’s sponsorship of research.

Then, last month, The New York Times reported that NIAAA had “waged a vigorous campaign to court the alcohol industry.” One slide from the agency presented to an industry audience states, “A definitive clinical trial represents a unique opportunity to show that moderate alcohol consumption is safe and lowers risk of common diseases.”

Siegel, who reviewed the presentation, told the Times that the study “is not public health research—it’s marketing. . . . They’re admitting the trial is designed to provide a justification for moderate drinking. That’s not objective science.”

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.